Calypso Medical Technologies of Seattle has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market a new Dynamic Edge gating technology for its Calypso system.
The technology is designed to automate the response to organ motion that occurs during the delivery of radiation to prostate cancer tumors in order to protect healthy tissue from unintended radiation. As a result, the technology may decrease the side effects associated with prostate radiation therapy, such as bowel and bladder incontinence and sexual dysfunction.
The Dynamic Edge gating feature will be compatible with linear accelerators manufactured by Siemens Healthcare of Malvern, PA, and Varian Medical Systems of Palo Alto, CA.
Related Reading
Calypso signs European sales pact with Siemens, September 2, 2010
Calypso wraps up first U.K. install, March 17, 2010
Calypso closes $50M funding, September 18, 2009
Calypso aligns with Varian Medical, July 24, 2009
Calypso installs 4D system in Miami, May 1, 2009
Copyright © 2010 AuntMinnie.com
